FHI Clinical Africa campaign focuses on importance of long-standing relationships, local teams and broad expertise as keys to successful research in the region
A webinar followed, featuring South Africa–based researchers discussing Africa’s potential for clinical research. Follow-up blog posts explored the wide variety of research opportunities in infectious diseases, neglected tropical diseases and emerging and reemerging diseases, as well as the maturation and expansion of research capacity in the region. Commitments by local governments and organizations to foster research and innovation have contributed to significant increases in the range of indications being studied.
A project profile video highlighted the importance of investigating existing treatments for their efficacy to treat COVID-19 in countries with limited access to new treatments, such as Ghana. A campaign video also described strategies for effective participant recruitment and retention for clinical studies being conducted in Africa.
FHI Clinical has a long history of working in sub-Saharan Africa; its parent company, FHI 360, began work in the region more than 50 years ago, and FHI Clinical has had staff on the ground throughout the region, including 250+ employees supporting the PREVAIL network. After acquiring the clinical trials business of Triclinium Clinical Development Proprietary Limited (TCD) in February of this year, FHI Clinical expanded its share of the clinical development market to become the dominant service provider in sub-Saharan Africa.
Local partners and sustainable research capacity
Responsive and adaptable
Sanchia Theron, Global Head, Medical Affairs, will also present “Tuberculosis (TB): the Silent ‘Pandemic’ the World Has Forgotten” on October 14 at 10:30 am CEST. Please visit https://www.fhiclinical.com/event/world-vaccine-congress-europe-2022/ to learn more and to book a meeting with the team.